Skip to content

Homepage

Author: Aura Biosciences, Inc.

Posted Date:

July 8, 2026

Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors

Aura Biosciences, Inc.

July 8, 2026
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Aura Biosciences, Inc.

June 1, 2026
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aura Biosciences, Inc.

May 19, 2026
Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences, Inc.

May 12, 2026
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

Aura Biosciences, Inc.

May 11, 2026
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Aura Biosciences, Inc.

May 5, 2026
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

Aura Biosciences, Inc.

May 4, 2026
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aura Biosciences, Inc.

May 4, 2026
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

Aura Biosciences, Inc.

May 4, 2026
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Aura Biosciences, Inc.

March 30, 2026

1 2